About Mitapivat
A Study Drug With Potential
Why Study Mitapivat Now
Mitapivat has the potential to improve energy and reduce sickling of red blood cells. The goal of RISE UP is to learn the effectiveness and safety of mitapivat in treating pain crises and anemia. If approved by the FDA, mitapivat will be a new kind of therapy for sickle cell disease.
The mitapivat molecule attaches to an enzyme in the red blood cell responsible for the production of energy. This has the potential to improve energy and reduce sickling of red blood cells.
Get the facts
There's a lot of information out there. Feel free to ask questions so you're comfortable joining the clinical trial. If you decide to join, your health and safety is the number one priority. Learn more on the Myths vs Facts page.
Sickle Cell Warrior
Sickle Cell Warrior
GET READY FOR THE NEXT PHASE OF RISE UP
Learn more about RISE UP, including full enrollment details, all study objectives, and key inclusion and exclusion details. Then talk to your eligible patients about the study.
If you have questions, email:
medinfo@agios.com (US)
ex-usmedinfo@agios.com (outside US)
